Cellebrite DI Ltd. $CLBT Shares Purchased by Migdal Insurance & Financial Holdings Ltd.

Migdal Insurance & Financial Holdings Ltd. increased its position in shares of Cellebrite DI Ltd. (NASDAQ:CLBT) by 28.6% during the 4th quarter, HoldingsChannel reports. The fund owned 1,350,000 shares of the company’s stock after acquiring an additional 300,000 shares during the quarter. Migdal Insurance & Financial Holdings Ltd.’s holdings in Cellebrite DI were worth $24,341,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Financial Management Professionals Inc. acquired a new position in shares of Cellebrite DI during the 3rd quarter valued at about $28,000. CWM LLC boosted its position in shares of Cellebrite DI by 85.7% during the 3rd quarter. CWM LLC now owns 1,560 shares of the company’s stock valued at $29,000 after acquiring an additional 720 shares during the last quarter. Advisory Services Network LLC acquired a new position in shares of Cellebrite DI during the 3rd quarter valued at about $40,000. Pacer Advisors Inc. boosted its position in shares of Cellebrite DI by 523.4% during the 3rd quarter. Pacer Advisors Inc. now owns 2,743 shares of the company’s stock valued at $51,000 after acquiring an additional 2,303 shares during the last quarter. Finally, First Horizon Corp boosted its position in shares of Cellebrite DI by 421.8% during the 4th quarter. First Horizon Corp now owns 2,891 shares of the company’s stock valued at $52,000 after acquiring an additional 2,337 shares during the last quarter. Institutional investors and hedge funds own 45.88% of the company’s stock.

Analyst Ratings Changes

CLBT has been the topic of several recent research reports. Needham & Company LLC lowered their price target on shares of Cellebrite DI from $24.00 to $18.00 and set a “buy” rating on the stock in a research report on Thursday, February 12th. Wall Street Zen raised shares of Cellebrite DI from a “sell” rating to a “hold” rating in a research report on Sunday, March 15th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Cellebrite DI in a research report on Monday, December 29th. Four equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Cellebrite DI currently has a consensus rating of “Moderate Buy” and an average target price of $22.50.

Cellebrite DI Trading Down 1.0%

Shares of CLBT opened at $13.25 on Wednesday. The firm has a market cap of $3.31 billion, a P/E ratio of 42.74, a price-to-earnings-growth ratio of 2.05 and a beta of 1.28. Cellebrite DI Ltd. has a 12-month low of $11.02 and a 12-month high of $20.53. The company’s 50-day moving average price is $13.77 and its 200 day moving average price is $16.15.

Cellebrite DI (NASDAQ:CLBT) last issued its quarterly earnings data on Wednesday, February 11th. The company reported $0.14 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.14. The firm had revenue of $128.82 million for the quarter, compared to analyst estimates of $126.07 million. Cellebrite DI had a net margin of 16.47% and a return on equity of 20.43%. Cellebrite DI’s revenue was up 28.8% on a year-over-year basis. During the same period in the previous year, the firm earned $0.10 EPS. Equities research analysts forecast that Cellebrite DI Ltd. will post 0.43 earnings per share for the current year.

About Cellebrite DI

Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company’s technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.

The company’s flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows.